Higher vitamin D levels in HIV-infected out-patients on treatment with boosted protease inhibitor monotherapy

HIV Medicine

Volumn 14, Issue 9, 2013, Pages 556-562

  Cervero, Miguel ^a   Agud, J L ^a   Torres, R ^a   Garcia Lacalle C ^a   Alcazar V ^a   Jusdado, J J ^a   Moreno, S ^b  

^a HOSPITAL SEVERO OCHOA   (Spain)

^b Madrid Hospital   (Spain)

Author keywords

Antiretroviral therapy; Combination antiretroviral therapy; Deficiency; Highly active antiretroviral therapy; HIV; Regimen; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; BOOSTED PROTEASE INHIBITOR; CALCIUM; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS 1 RNA; PARATHYROID HORMONE; PROTEINASE INHIBITOR; RNA; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ALBUMIN BLOOD LEVEL; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; ATTRIBUTABLE RISK; CALCIUM BLOOD LEVEL; CAUCASIAN; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; DISEASE TRANSMISSION; DRUG USE; ETHNIC DIFFERENCE; FEMALE; GENE DOSAGE; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INJECTING DRUG USER; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MONOTHERAPY; NUTRITIONAL STATUS; OUTPATIENT; PARATHYROID HORMONE BLOOD LEVEL; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT DURATION; VIRUS LOAD; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D INSUFFICIENCY; VITAMIN D OPTIMAL; VITAMIN DEFICIENCY;

ANTIRETROVIRAL THERAPY; COMBINATION ANTIRETROVIRAL THERAPY; DEFICIENCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV; REGIMEN; VITAMIN D;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; FEMALE; HELIOTHERAPY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; OUTPATIENTS; SPAIN; VIRAL LOAD; VITAMIN D; VITAMIN D DEFICIENCY; YOUNG ADULT;

EID: 84883452306     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12049     Document Type: Article

References (25)

1. Brown T, Qaqish R. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20: 2164-2174.
2. McComsey GA, Tebas P, Shane E etal. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Iinfect Dis 2010; 51: 937-946.
3. Collin F, Duval X, Le Moing V etal. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 2009; 23: 1021-1024.
4. Womack J, Goulet J, Gibert C etal. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS ONE 2011; 6: e17217.
5. Mueller NJ, Fux CA, Ledergerber B etal. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS 2010; 24: 1-8.
6. Wasserman P, Rubin DS. Highly prevalent vitamin D deficiency and insufficiency in an urban cohort of HIV-infected men under care. AIDS Patient Care STDS 2010; 24: 223-227.
7. Dao CN, Patel P, Overton ET etal. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a Cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52: 396-405.
8. Cervero M, Agud J, García-Lacalle C etal. Prevalence of vitamin D deficiency and its related risk factor in a Spanish Cohort of adult HIV-infected patients: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2012; 28: 963-971.
9. Adeyemi OM, Agniel D, French AL etal. Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr 2011; 57: 197-204.
10. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
11. Overton E, Yin MT. The rapidly evolving research on vitamin D among HIV-infected populations. Curr Infect Dis Rep 2011; 13: 83-93.
12. Welz T, Childs K, Ibrahim F etal. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24: 1923-1928.
13. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M etal. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24: 1375-1382.
14. Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther 2010; 15: 425-429.
15. Wohl D, Doroara M, Pilotto JH etal. Change in Vitamin D levels smaller of development of severe Vitamin D Deficiency lower among HIV-1 infected, Treatment-naive adults receiving TMC278 compared with EFV: 48-weeks result from the Phase III ECHO trial [O].1014]. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February-March 2011.
16. Fox J, Peters B, Prakash M etal. Improvement in vitamin D deficiency following antiretroviral regime changes: results from the MONET trial. AIDS Res Hum Retroviruses 2011; 27: 29-34.
17. Kim J, Gandhi V, Psevdos G etal. Evaluation of vitamin D levels among HIV-infected patients in New York City. AIDS Res Hum Retroviruses 2012; 28: 235-241.
18. Panel on Clinical. Practices for the treatment of HIV infection. Spanish Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Consensus document GESIDA and PNS on antiretroviral treatment in adults, December 29, 2010. Available at www.gesida-seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2012-Documentoconsenso-TAR-adulto-verordenador.pdf.
19. Heaney RP, Dowell MS, Hale CA etal. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003; 22: 142-146.
20. Bischoff-Ferrari HA, Willett WC, Wong JB etal. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 2009; 169: 551-561.
21. Clemens TL, Adams JS, Henderson SL etal. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982; 8263: 74-76.
22. Rosenvinge MM, Gedela K, Copas AJ etal. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr 2010; 54: 496-499.
23. Mehta S, Spiegelman D, Magusi F etal. Vitamin D HIV-related complications and HIV disease progression women in Tanzania. AIDS Patient Care STDS 2011; 25: 579-585.
24. Terrier B, Carrat F, Geri G etal. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol 2011; 55: 756-761.
25. Cozzolino M, Vidal M, Arcidiacono MV etal. HIV-protease inhibitors impair vitamin D bioactivation to 1, 25-dihydroxyvitamin D. AIDS 2003; 17: 513-520.